首页 | 本学科首页   官方微博 | 高级检索  
检索        

参松养心胶囊对阵发性心房颤动患者P波离散度及高敏C-反应蛋白和白细胞介素-6的影响
引用本文:刘新灿,陈晓玲,张正勋,朱明军,朱翠玲.参松养心胶囊对阵发性心房颤动患者P波离散度及高敏C-反应蛋白和白细胞介素-6的影响[J].河南中医药学刊,2012(6):750-752.
作者姓名:刘新灿  陈晓玲  张正勋  朱明军  朱翠玲
作者单位:河南中医学院第一附属医院,河南郑州450000
基金项目:河南省教育厅自然科学基金(编号:200820148)
摘    要:目的:探讨参松养心胶囊对阵发性房颤患者的P波离散度(Pd)、高敏C-反应蛋白(hsCRP)和白细胞介素-6(IL-6)的影响。方法:76例患者分为3组,对照组、参松养心组和常规治疗组。30例窦性心律患者作为对照组,其中原发性高血压病患者21例,冠状动脉性心脏病患者9例,均按心内科常规药物治疗(高血压患者根据病情选用ARB、CCB和利尿剂,冠状动脉性心脏病患者根据病情选用β受体阻滞剂、他汀类和硝酸酯类药物)。46例阵发性心房颤动患者随机分成常规治疗组23例和参松养心组23例,常规治疗组只治疗基础性疾病(高血压患者根据病情选用ARB、CCB和利尿剂,冠状动脉性心脏病患者根据病情选用β受体阻滞剂、他汀类和硝酸酯类药物),参松养心组在治疗基础性疾病同时予以参松养心胶囊。分别于治疗前、治疗3个月后测定Pd、hsCRP、IL-6水平,并分析与房颤的关系。结果:治疗前常规治疗组和参松养心组中Pd、hsCRP和IL-6水平均明显高于对照组(均为P〈0.05)。治疗后常规治疗组Pd、hsCRP和IL-6水平较治疗前的基线水平无明显变化(P〉0.05),而参松养心组Pd、hsCRP、IL-6水平相比较治疗前明显降低(P〈0.05)。结论:参松养心胶囊可使阵发性房颤患者P波离散度减小,使增高的hsCRP和IL-6水平显著降低。参松养心胶囊对阵发性房颤患者房颤的复发有一定的防治作用。

关 键 词:参松养心胶囊  阵发性房颤  窦性心律  高血压  冠状动脉性心脏病  P波离散度  C-反应蛋白  白细胞介素-6

Effect of Shensong Yangxin Capsule on P-wave Dispersion Degree, High Sensitivity C.Reactive Protein and Interleukin-6 in Patients with Paroxysmal Atrial Fibrillation
Institution:Liu Xincan, Chen Xiaoling, Zhang Zhengxun,Zhu Mingjun, Zhu Cuffing ( The First Affiliated Hospital of Henan University of TCM, Zhengzhou, Henan, China 450000)
Abstract:Objective :To discuss the effect of Shensong Yangxin Capsule on pwave dispersion degree, high sensitivity creactive protein and Interleukin6 in patients with paroxysmal atrial fibrillation. Methods :76 patients were divided into three groups, the control group, the Shensong Yangxin group,the routine treatment group. 30 cases of sinus rhythmia patients (including 21 cases of primary hyperten sion patients and 9 cases of CHD patients) were in the control group, and treated with conventional drugs in cardiology department ( ARB, CCB and uretic drugs were used for hypertension patients ; β-receptor retardant, Stations and nitrate drugs were used for CHD pa tients). The other 46 cases of paroxysmal atrial fibrillation were randomly divided into the routine treatment group and the Shensong Yangxin Group with each of 23 patients. The routine treatment group only treated primary disease (ARB, CCB and uretic drugs were used in hypertension patients according to their disease conditions;β-receptor retardant, Stations and nitrate drugs were used in CHD patients according to their disease conditions). Shensong Yangxin Group was mainly treated by Shensong Yangxin Capsule (produced by Yiling Pharmaceutical Limited Company in Hebei Province,4 Capsules once,3 times per day). Levels of Pd, hsCRP and IL6 were de termined before the treatment and 3 months after the treatment, then the relationship between them and atrial fibrillation was analyzed. Results:Before the treatment,levels of Pd,hsCRP and IL-6 in the routine treatment group and the Shensong Yangxin group were obvi ously higher than the control group(P 〈0.05). After the treatment,levels of Pd,hsCRP and IL6 in the routine treatment group had no obvious changes compared with the baseline level before treatment( P 〉 0.05 ), but levels of Pd,hsCRP and IL6 in Shensong Yangxin group were much lower than the level before treatment ( P 〈 0.05 ). Conclusion : Shensong Yangxin Capsule can decrease the Pwave dispersion degree of paroxysmal atrial fibrillation patients, reduce the increased hsCRP and IL6 level,which has certain preventive and curative effects on the recurrence of paroxysmal atrial fibrillation.
Keywords:shensong yangxin capsule  paroxysmal atrial fibrillation  sinus rhythmia  hypertension  coronary artery heart disease  P-wavedispersion degree  C-reactive protein  Interleukin-6
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号